Ozempic maker Novo says ‘scared’ snack food CEOs are calling him for advice

Makers of everything from snack food to knee implants are facing a potential threat from Novo Nordisk’s powerful appetite-suppressing treatments. So they’re calling the drugmaker for advice.

“A couple of CEOs from, say, food companies have been calling me,” Novo chief executive Lars Fruergaard Jorgensen said during a wide-ranging discussion in New York. He declined to name names, saying questions had centred on how the drugs work and how fast they would roll out.

“They are scared about it.”

The impact of the drugs, including Ozempic and Wegovy, could vary across industries, Mr Jorgensen said. He pointed to the success of clinical trials of Wegovy on weight-linked ailments like kidney disease and knee arthritis, as well as recent Wall Street research showing a small change in consumer behavior can have major financial implications.

The new class of drugs known as GLP-1s, prescribed for diabetes as well as obesity, cause weight loss at levels previously achievable only with surgery. With a new competitor from Eli Lilly & Co, Zepbound, on the market since December, Bloomberg Intelligence estimates the weight-loss market alone could reach $US80 billion ($123b) by 2030.

That’s left companies from Walmart to Chipotle Mexican Grill grappling with how a less hungry, potentially healthier customer will affect business. Some, like Chipotle, have said fresh food will still appeal to people who are trying to lose weight.

French company Danone, which makes popular yogurt brands, also sees GLP-1 drugs boosting business. People taking drugs like Ozempic and Wegovy are “looking for products with high protein and low fat content”, Danone’s chief financial officer Juergen Esser said on a call last year.

Others are watching and waiting. Conagra Brands CEO Sean Connolly told analysts last year the snackmaker has “an entire department of demand scientists” studying changes in consumer behaviour every day.

“There’s still so many unknowns regarding the rate of adoption, the impact on food choices,” Hershey Co. CEO Michele Buck said on a call last year. “We’re doing more work constantly to understand those future potential impacts on our categories.”

Supply struggles

Thus far, the impact of Wegovy and Ozempic has been moderated by Novo’s struggles to meet demand.

Mr Jorgensen pointed to Novo’s $US11b acquisition of three Catalent factories as key to boosting production.

He said Novo will put its own quality control processes in place at the factories. Catalent has faced production issues with some of its orders, including Moderna’s COVID vaccine and a widely used eye drug from Regeneron Pharmaceuticals. Getting a site up to speed can slow productivity in the short term, Mr Jorgensen said.

In the long term, Novo will be able to use Catalent’s capacity more efficiently and boost supply, Mr Jorgensen said. He predicted that Novo will be able to make obesity drugs available not just “for the rich, but actually for the many”.

“Demand is much bigger than what we can supply today,” he said.

He predicted that Lilly’s entry into the market will benefit Novo, too. “If there’s one more company going out and convincing employers to opt in for obesity coverage, that’s actually a bigger benefit than a competitive threat.”

Bloomberg